scholarly journals Circulating sphingomyelins on estrogen receptor-positive and estrogen receptor-negative breast cancer-specific survival

2020 ◽  
pp. BMT42
Author(s):  
Charleen D Adams
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Breast Cancer Specific Survival ◽  
Low Density Lipoprotein Cholesterol ◽  
Cancer Specific Survival ◽  
Estrogen Receptor Positive ◽  
Estrogen Receptor Negative

Aim: This study aims to determine whether a causal relationship exists between circulating sphingomyelins and breast cancer-specific survival, since, if one does, sphingomyelins could be studied as a therapeutic target in the management of breast cancer. Patients/materials & methods: Mendelian randomization is used here to investigate whether higher levels of circulating sphingomyelins impact breast cancer-specific survival for estrogen receptor-negative (ER–) and estrogen receptor-positive (ER+) patients. Results: The results suggest a null effect of sphingomyelins for ER– breast cancer-specific survival and a protective effect for ER+ breast cancer-specific survival. Sensitivity analyses implicate low-density lipoprotein cholesterol as a potential confounder. Conclusion: Future studies should replicate and triangulate the present findings with other methods and tease out the roles of sphingomyelins and low-density lipoprotein cholesterol on breast cancer-specific survival.

scholarly journals G-Protein Estrogen Receptor as a Regulator of Low-Density Lipoprotein Cholesterol Metabolism

2015 ◽  
Vol 35 (1) ◽  
pp. 213-221 ◽  
Author(s):  
Yasin Hussain ◽  
Qingming Ding ◽  
Philip W. Connelly ◽  
J. Howard Brunt ◽  
Matthew R. Ban ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
G Protein ◽  
Cholesterol Metabolism ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol

scholarly journals The association between low-density lipoprotein cholesterol predicted by HMGCR genetic variants and breast cancer risk may be mediated by body mass index

2018 ◽  
Author(s):  
Siddhartha P. Kar ◽  
Hermann Brenner ◽  
Graham G. Giles ◽  
Dezheng Huo ◽  
Roger L. Milne ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Nucleotide Polymorphisms ◽  
Low Density Lipoprotein Cholesterol ◽  
Genome Wide ◽  
A Genome ◽  
Mr Study

Orho-Melander et al. recently reported that lower low-density lipoprotein cholesterol (LDLC) as predicted by the T-allele of the variant rs12916 in HMGCR is associated with a decreased risk of developing breast cancer [odds ratio (OR) = 0.89; 95% confidence interval (CI): 0.82–0.96].1 This analysis was embedded in a wider Mendelian randomization (MR) study performed using genotype data from a prospective cohort of 26,589 individuals that included 16,022 women and 1176 incident breast cancer cases. HMGCR encodes 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the enzyme inhibited by statins. The T-allele of rs12916 is associated with reduced HMGCR expression and therefore, in principle, its effects should be analogous to the effects of lifelong statin administration starting at birth.2 The MR study of Orho-Melander et al. also found that a genome-wide LDLC score based on 32 independent LDLC-associated single nucleotide polymorphisms (SNPs) was not associated with breast cancer. In light of this finding, they suggest that the protective effect of the rs12916 T-allele on breast cancer may either be specific to LDLC lowering via genetic inhibition of HMGCR or be the result of a distinct mechanism that is regulated by rs12916 and HMGCR.

Sign in / Sign up

Export Citation Format

Share Document